Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 3, 1996, Pages 213-220

  Bolmstedt, Anders ^a   Sjölander, Sigrid ^b   Hansen, John Erik S ^c   Åkerblom, Lennart ^b   Hemming, Anna ^a   Hu, Shiu Lok ^d   Morein, Bror ^b   Olofsson, Sigvard ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c HVIDOVRE HOSPITAL   (Denmark)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

gp120 N linkage; HIV 1; Immunogen; Oligosaccharide

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCAN DERIVATIVE; GLYCOPROTEIN GP 160; NEUTRALIZING ANTIBODY; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; GUINEA PIG; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; SITE DIRECTED MUTAGENESIS; VIRUS ENVELOPE; VIRUS NEUTRALIZATION;

EID: 0030016341     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199607000-00001     Document Type: Article

References (43)

1. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J Biol Chem 1990;265:10373-82.
2. Ratner L, Haseltine W, Patarca R, et al. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 1985; 313:277-84.
3. Montreuil J. Structure and conformation of glycoprotein gly-cans. In: Olden K, Parent JB, eds. Vertebrate lectins. New York: Van Nostrand, 1987:1-26.
4. Olofsson S, Jeansson S, Hansen J-ES. Use of lectins in general and diagnostic virology. In: Doyle RJ, Slifkin M, eds. Lectin-microorganism interactions. New York: Marcel Dekker, 1994:67-109.
5. Hansen JE. Carbohydrates of human immunodeficiency virus. APMIS Suppl 1992;27:96-108.
6. Alexander S, Elder JH. Carbohydrate dramatically influences immune reactivity of antisera to viral glycoprotein antigens. Science 1984;226:1328-30.
7. Delmas B, Laude H. Carbohydrate-induced conformation changes strongly modulate the antigenicity of coronavirus TGEV glycoproteins S and M. Virus Res 1991;20:107-20.
8. Back NK, Smit L, De Jong JJ, et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994;199:431-8.
9. Benjouad A, Gluckman JC, Rochat H, Montagnier L, Baharoui E. Influence of carbohydrate moieties on the immunogenicity of human immunodeficiency virus type 1 recombinant gp160. J Virol 1992;66:2473-83.
10. Benjouad A, Gluekman JC, Montagnier L, Bahraoui E. Specificity of antibodies against native or desialylated human immunodeficiency virus type 1 recombinant gp160. J Virol 1993;67:1693-7.
11. Bolmstedt A, Hemming A, Flodby P, et al. Effects of mutations in disulfide bonds and glycosylation sites on the processing, CD4-binding, and fusion activity of HIV glycoproteins. J Gen Virol 1991;72:1269-77.
12. Bolmstedt A, Olofsson S, Sjögren-Jansson E, et al. Carbohydrate determinant NeuAc-Galβ1-4 of N-linked glycans modulating the antigenic activity of human immunodeficiency virus type 1 glycoprotein gp120. J Gen Virol 1992;73: 3099-105.
13. Davis D, Stephens D, Willers C, Lachmann P. Glycosylation governs the binding of peptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol 1990; 71:2289-98.
14. Neurath A, Strick N, Lee ES. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19-36-residue) synthetic peptides. J Gen Virol 1990;71: 85-95.
15. Hemming A, Lundberg L, Olofsson S. A strategy simplifying site directed mutagenesis in the CD4-binding region of HIV gp120. Arch Virol 1989;107:301-5.
16. Hemming A, Bolmstedt A, Jansson B, Hansen J-ES, Hu S-L, Olofsson S. Identification of three N-linked glycans in the V4-V5 region, dispensable for CD4-binding and fusion activity of gp120. Arch Virol 1994;134:335-44.
17. Myers G, Korber B, Berzofsky JA, Smith RF, Pavlakis GN. Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences. Los Alamos: Los Alamos National Laboratory, 1994:
18. Hemming A, Bolmstedt A, Flodby P, et al. Cystein 402 of HIV gp120 is essential for CD4-binding and resistance of gp120 to intracellular degradation. Arch Virol 1989;109:269-76.
19. Hu S-L, Kosowski SG, Dalrymple JM. Expression of AIDS virus envelope gene in recombinant vaccinia viruses. Nature 1986;320:537-40.
20. Klaniecki J, Dykers T, Travis B, et al. Cross-neutralizing antibodies in rabbits immunized with HIV gp160 purified from simian cells infected with a recombinant vaccinia virus. AIDS Res Hum Retroviruses 1991;7:791-8.
21. Morein B, Sundquist B, Höglund S, Dalsgaard K, Osterhaus A. Iscom - a novel structure for antigen presentation of membrane proteins from enveloped viruses. Nature 1984; 308:457-60.
22. Åkerblom L, Nara P, Dunlop N, Morein B. Cross-neutralizing antibodies to HIV-1 in mice after immunization with gp160 iscoms. AIDS Res Hum Retroviruses 1991;7: 621-7.
23. Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M. Nucleotide sequence of the AIDS virus, LAV. Cell 1985;40: 9-17.
24. Gram GL, Hemming A, Bolmstedt A, et al. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch Virol 1994;139:253-61.
25. Lövgren K, Lindmark J, Pipkorn R, Morein B. Antigenic presentation of small molecules and peptides conjugated to a performed iscom as carrier. J Immunol Methods 1987;98: 137-43.
26. Hansen J-ES, Nielsen C, Arendrup M, et al. Broadly neutralizing antibodies targeted to mucin-type carbohydrate epitopes of human immunodeficiency virus. J Virol 1991;65: 6461-7.
27. Shutten M, McKnight A, Huisman RC, et al. Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies. AIDS 1993;7:919-23.
28. Åkerblom L, Hinkula J, Broliden PA, et al. Neutralizing cross-reactive and non-neutralizing monoclonal antibodies to HIV-1 gp120. AIDS 1990;4:953-60.
29. de Vreis P, Heeney JL, Boes J, et al. Protection of rhesus maqaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994;12:1443-52.
30. Putkonen P, Björling E, Åkerblom L, et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J Acquir Immune Defic Syndr 1994;7:551-9.
31. Schønning K, Jansson B, Olofsson S, Hansen J-ES. Rapid selection of an N-linked oligosaccharide by monoclonal antibodies against the V3-loop of HIV-1. J Gen Virol 1996; 77:753-8.
32. Wyatt R, Thali M, Tilley S, et al. Relationship of the human immunodeficiency virus type 1 gp120 third variable loop to a component of the CD4-binding site in the fourth conserved region. J Virol 1992;66:6997-7004.
33. Golding H, D'Souza P, Bradac J, Mathieson B, Fast P. Neutralization of HIV-1. AIDS Res Hum Retroviruses 1994;10: 633-43.
34. Olofsson S, Sjöblom I, Jeansson S. Activity of herpes simplex virus type 1-specified glycoprotein C antigenic site II epitopes modulated by peripheral fucose or galactose units of glycoprotein oligosaccharides. J Gen Virol 1990;71:889-95.
35. McKeating JA, Shotton C, Cordell J, et al. Characterization of neutralizing antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 1993;67:4932-44.
36. Broder CC, Earl PL, Long D, Abedon ST, Moss B, Doms RW. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies. Proc Natl Acad Sci USA 1994;9124:11699-703.
37. Earl PL, Broder CC, Long D, et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J Virol 1994;68:3015-26.
38. Sattentau QJ, Moore JP. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp 120 oligomer. J Exp Med 1995;182:185-96.
39. Sullivan N, Sun Y, Li J, Hofmann W, Sodroski J. Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates. J Virol 1995;69:4413-22.
40. Schønning K, Jansson B, Olofsson S, Nielsen JO, Hansen J-ES. Shielding of a principal neutralizing epitope of HIV-1 caused by an N-linked oligosaccharide is dependent on the quatenary structure of the HIV-1 envelope oligomer. Virology 1996;218:134-40.
41. Botarelli P, Houlden BA, Haigwood NL, Servis C, Montagna D, Abrignani S. N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes. J Immunol 1991;147: 3128-32.
42. Doe B, Steimer KE, Walker CM. Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO-derived gp120 is enhanced by enzymatic removal of N-linked glycans. Eur J Immunol 1994;24:2369-76.
43. Sjölander S, Bolmstedt A, Åkerblom L, et al. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Virology 1996;215:124-33.